SCHEMBL11996040

SCHEMBL11996040

CCCCCCCCCCCCc1ccc(C(=O)N2CCC[C@H]2C(=N)N)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
SPHK1 Q9NYA1 17/20 1.00
SPHK2 Q9NRA0 7/20 1.00
L3MBTL1 Q9Y468 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11996042 1.00 SPHK1 (1.00) SPHK1SPHK2L3MBTL1
SCHEMBL11996036 1.00 SPHK1 (1.00) SPHK1SPHK2L3MBTL1
SCHEMBL16945694 1.00 SPHK1 (1.00) SPHK1SPHK2L3MBTL1
SCHEMBL18025375 1.00 SPHK1 (1.00) SPHK1SPHK2L3MBTL1
SCHEMBL11996038 1.00 SPHK1 (1.00) SPHK1SPHK2L3MBTL1
SCHEMBL11996034 1.00 SPHK1 (1.00) SPHK1SPHK2L3MBTL1
Hydrochloric Acid SCHEMBL27165616 0.99 SPHK1 (1.00) SPHK1SPHK2L3MBTL1
Hydrochloric Acid SCHEMBL27165704 0.99 SPHK1 (1.00) SPHK1SPHK2L3MBTL1
SCHEMBL18969864 0.89 SPHK1 (0.80) SPHK1SPHK2L3MBTL1
SCHEMBL18969861 0.89 SPHK1 (0.80) SPHK1SPHK2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3223807-B1 METHOD OF PREVENTING OR TREATING A PULMONARY DISEASE OR CONDITION UNIV ILLINOIS (US) 2021-09-15 EP disclosed
US-11026918-B2 Method of preventing or treating a pulmonary disease or condition THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2021-06-08 US disclosed
US-20210040215-A1 METHODS FOR ENHANCING THE POTENCY OF THE IMMUNE CHECKPOINT INHIBITORS Université Toulouse III - Paul Sabatier (FR) 2021-02-11 US disclosed
US-10822415-B2 Methods for enhancing the potency of the immune checkpoint inhibitors INSERM (INSTITUT NATIONAL DE LA SANTÉET DE LA RECHERCHE MÉDICALE) (FR) 2020-11-03 US disclosed
US-20190031757-A1 METHODS FOR ENHANCING THE POTENCY OF THE IMMUNE CHECKPOINT INHIBITORS INSERM (Institut National de la Santé et de la Recherche Médicale (FR) 2019-01-31 US disclosed
US-9908849-B2 Imidamide sphingosine kinase inhibitors UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2018-03-06 US disclosed
US-9908849-B2 Imidamide sphingosine kinase inhibitors UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2018-03-06 US disclosed
US-20170360749-A1 METHOD OF PREVENTING OR TREATING A PULMONARY DISEASE OR CONDITION NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-12-21 US disclosed
US-20170360749-A1 METHOD OF PREVENTING OR TREATING A PULMONARY DISEASE OR CONDITION NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-12-21 US disclosed
US-20170166525-A1 IMIDAMIDE SPHINGOSINE KINASE INHIBITORS UNIVERSITY OF VIRGINIA 2017-06-15 US disclosed
US-20170166525-A1 IMIDAMIDE SPHINGOSINE KINASE INHIBITORS UNIVERSITY OF VIRGINIA 2017-06-15 US disclosed
US-9421177-B2 Imidamide sphingosine kinase inhibitors UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2016-08-23 US disclosed
WO-2016085933-A1 METHOD OF PREVENTING OR TREATING A PULMONARY DISEASE OR CONDITION THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2016-06-02 WO disclosed
US-20120214858-A1 IMIDAMIDE SPHINGOSINE KINASE INHIBITORS UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2012-08-23 US disclosed
WO-2011020116-A1 IMIDAMIDE SPHINGOSINE KINASE INHIBITORS UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2011-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190031757-A1 METHODS FOR ENHANCING THE POTENCY OF THE IMMUNE CHECKPOINT INHIBITORS CD274, PDCD1, PDCD1LG2 SPHK1 96/4885SPHK2 270/4885L3MBTL1 2193/4885
US-11026918-B2 Method of preventing or treating a pulmonary disease or condition SPHK1, SPHK2, SMPD3 SPHK1 1/4885SPHK2 2/4885L3MBTL1 4037/4885
US-20170360749-A1 METHOD OF PREVENTING OR TREATING A PULMONARY DISEASE OR CONDITION SPHK1, SPHK2, SMPD3 SPHK1 1/4885SPHK2 2/4885L3MBTL1 4037/4885
US-20210040215-A1 METHODS FOR ENHANCING THE POTENCY OF THE IMMUNE CHECKPOINT INHIBITORS CD274, PDCD1, PDCD1LG2 SPHK1 96/4885SPHK2 270/4885L3MBTL1 2193/4885
US-10822415-B2 Methods for enhancing the potency of the immune checkpoint inhibitors CD274, PDCD1, PDCD1LG2 SPHK1 96/4885SPHK2 270/4885L3MBTL1 2193/4885
US-20120214858-A1 IMIDAMIDE SPHINGOSINE KINASE INHIBITORS SPHK2, SPHK1, S1PR2 SPHK1 2/4885SPHK2 1/4885L3MBTL1 2676/4885
US-20170166525-A1 IMIDAMIDE SPHINGOSINE KINASE INHIBITORS SPHK2, SPHK1, S1PR2 SPHK1 2/4885SPHK2 1/4885L3MBTL1 2676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.